Prognostic Parameters for the Primary Care of Melanoma Patients : What Is Really Risky in Melanoma?

الملخص EN

Due to intensified research in recent years, the understanding of the molecular mechanisms involved in the development of melanoma has dramatically improved.

The discovery of specific, causal mutations such as BRAF or KIT oncogenes not only renders a targeted and thus more effective therapeutic approach possible, but also gives rise to a new genetic-based classification.

Targeting just a few out of several potential mutations, BRAF-Inhibitors such as PLX 4032 achieved already tremendous results in the therapy of metastatic melanoma.

Up to now, the correlation of clinical, histomorphologic, and genetic features is, however, not understood.

Even more, is it not well known precisely what kind of molecular changes predispose the primary melanoma for metastasis.

The identification of morphological surrogates and prognostic parameters in tumors with such genetic alteration seems therefore crucial when differentiating and classifying this heterogeneous tumor entity in more detail and thus facilitates the stratification of prognosis as well as therapy.

This review summarizes the current understanding of carcinogenesis and gives a detailed overview of known morphologic and potentially future genetic prognostic parameters in malignant melanoma.